Viritis

Company Overview

Snapshot

Founded in August 2020 by Aaron Wis, Amit Turman, and Amit Philosoph, Viritis operates with 1–10 employees. The company has raised $665,000 across four funding rounds. In February 2025, Viritis secured funding from Road2, an accelerator, and also received a grant, signaling continued development in its antiviral platform.

Business overview

Viritis is a biotech company developing next-generation antisense-based antiviral drugs. Its core technology leverages AI-driven algorithms and patented molecule design to specifically bind to viral RNA, activating cellular defense mechanisms to degrade the virus without harming the host. The molecules naturally disintegrate within hours, leaving no harmful residues. Viritis serves the pharmaceutical and biotechnology sectors, focusing on developing scalable and precise solutions for current and emerging viral threats, with potential applications extending to cancer treatment.

Strategic signal

In September 2025, Nature Biotechnology highlighted Viritis's innovative use of AI to design antiviral antisense therapy drugs. This recognition underscores the company's advanced technological approach in targeting virus-specific RNA for degradation, positioning Viritis as a key player in the evolving landscape of antiviral research and development, particularly as public trust in traditional vaccines declines and funding shifts towards broader antiviral platforms.

Company Intelligence Q&A

What is Viritis's core technology for antiviral treatment?

Viritis develops a next-generation antisense-based platform that uses AI-driven algorithms and patented molecule design to bind specifically to viral RNA. This activates the cell’s innate defense mechanisms, degrading the virus from within without harming the host. The molecule then naturally disintegrates within hours.

What significant funding did Viritis secure in February 2025?

In February 2025, Viritis secured funding from Road2, an accelerator, and also received a grant. This contributed to the company's total raised capital of $665,000 across four funding rounds.

What is the strategic importance of Viritis's participation in the NVIDIA Inception Program?

Viritis is part of the NVIDIA Inception Program, which aids in enhancing its AI algorithms. This partnership is crucial for advancing the company's AI-driven drug design capabilities for antiviral therapies.

What are Viritis's future plans regarding clinical development and regulatory approval?

Viritis is preparing to enter clinical trials for its AI-driven antiviral drug and aims to secure FDA approval. The company's technology is designed to shorten development timelines for antivirals.

How does Viritis's technology address viral mutations?

Viritis's novel technology targets all strains of a given virus, offering a scalable and precise solution for current and emerging viral threats, including those with mutations. This approach provides a complementary strategy to vaccines.